on reta check ggt

Retatrutide is something called a triple receptor agonist, which means it activates three different hormonal pathways in the body at the same time. Those three pathways involve something called GLP-1, which helps regulate blood sugar and appetite, something called GIP, which works alongside GLP-1 to manage insulin release, and then a third one called glucagon, which plays a very different role than the other two.

Glucagon is a hormone your body normally releases when blood sugar gets too low, and its job is to signal the liver to make more glucose so the brain and muscles have fuel to work with. The process of the liver converting stored fat into glucose is called gluconeogenesis, which is just a scientific way of saying the liver builds new sugar out of non-sugar materials. When retatrutide activates the glucagon receptor, it is essentially sending that same signal artificially, telling the liver to start pulling fat stores and converting them even when blood sugar levels are not necessarily dropping.

When the liver gets that glucagon signal repeatedly, it goes into something like overdrive, pulling fat from tissues and releasing it into the bloodstream so it can be converted and used as fuel. That fat moving through the blood shows up in labs as elevated triglycerides and elevated LDL cholesterol, which is the type of cholesterol most people associate with cardiovascular risk. This does not automatically mean something harmful is happening, because the body is responding to a real signal from the drug, but it does mean the labs will look different than they normally would without context.

The liver enzymes that tend to rise during this process are another piece of the picture, and one of the more informative ones is something called GGT, which stands for gamma-glutamyltranspeptidase. GGT is an enzyme that lives primarily inside liver cells and along the bile ducts, and when liver cells are stressed or damaged, they leak GGT into the bloodstream, causing levels in the blood to rise. Measuring GGT gives a more direct window into how the liver tissue itself is tolerating the increased workload that comes with glucagon-driven fat mobilization.

Standard liver enzyme panels often include something called ALT and AST, which are also markers of liver stress, but GGT is particularly sensitive to changes in the liver's metabolic activity and bile flow. Because retatrutide is pushing the liver to process more fat than it might normally handle, checking GGT alongside the standard panel gives a clearer picture of whether the liver is adapting or actually being harmed. Research using imaging tools that can detect GGT activity in real time has confirmed that GGT behavior in the liver changes meaningfully under different metabolic conditions, which supports why tracking it matters during any therapy that heavily involves liver metabolism.

On the cholesterol side, the issue is not just how much LDL is in the blood but what kind of LDL it is, because LDL particles vary in size and density and some types are more likely to contribute to artery damage than others. Something called ApoB, which stands for apolipoprotein B, is a protein that sits on the surface of LDL particles and essentially one ApoB molecule exists per particle, so measuring ApoB tells you how many total LDL particles are circulating rather than just estimating their overall volume. A high LDL number with a low ApoB count might mean the particles are large and fewer in number, which carries less risk, while a high ApoB with even a moderate LDL number can suggest many small dense particles that are more likely to embed in artery walls.

Research published in 2025 looking at circulating proteins called ANGPTL3 and ANGPTL8 found that retatrutide treatment caused decreases in those proteins, and those decreases ran parallel to reductions in serum lipids, which suggests the drug is doing something more complex with fat metabolism than simply releasing fat into the blood without any regulatory control. A meta-analysis of randomized controlled trials looking at retatrutide's effects on blood pressure and lipid levels found that the drug's impact on lipids is real and measurable, which reinforces why monitoring them carefully matters. Animal model studies using diet-induced obese mice and hamsters also showed that retatrutide produces multiple metabolic benefits related to liver fat and metabolic dysfunction-associated steatohepatitis, which is a liver condition caused by fat buildup and inflammation.

Something called hs-CRP, which stands for high-sensitivity C-reactive protein, is a marker that the liver itself produces in response to inflammation anywhere in the body. When hs-CRP is elevated, it suggests there is an ongoing inflammatory process, and when it is elevated alongside high LDL and high ApoB, it changes the interpretation of the cholesterol picture considerably. An LDL particle floating in a blood vessel is much more likely to cause damage if the vessel wall is already inflamed, so hs-CRP adds a dimension to cardiovascular risk that the lipid numbers alone cannot capture.

Looking at these markers together, GGT for liver health, ApoB for particle count, and hs-CRP for inflammation, creates a fuller picture of what is actually happening inside the body when someone is using a drug that pushes the liver into a higher metabolic gear. Each number alone is incomplete because the liver, the lipid system, and the inflammatory system are all connected, and a drug that touches the glucagon pathway is touching all three at once. Understanding why the labs change and what each marker is actually measuring is what allows someone to tell the difference between a normal physiological response to the drug and a signal that something needs to be addressed.

References

1. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
2. Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
3. Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
4. Wen Y, Lemen D, Lin Y et al.. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025. Source
5. Briand F, Le Cudennec C, Grasset E et al.. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity Silver Spring. 2026. Source
6. Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev. 2026. Source
7. Højte C, Olsen MF, Faurholt-Jepsen D et al.. Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort. J Cyst Fibros. 2025. Source
8. Wang K, Chen XY, Zhang RW et al.. Multifunctional fluorescence/photoacoustic bimodal imaging of γ-glutamyltranspeptidase in liver disorders under different triggering conditions. Biomaterials. 2024. Source
9. Crepin S, Godet B, Carrier P et al.. Probable drug-induced liver injury associated with aliskiren: case report and review of adverse event reports from pharmacovigilance databases. Am J Health Syst Pharm. 2014. Source

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness